Journal
EXPERT REVIEW OF VACCINES
Volume 18, Issue 2, Pages 153-160Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/14760584.2019.1568876
Keywords
Cancer; eradication; gender-neutral vaccination; human papillomavirus; herd effect; impact; resilience; safety; vaccine efficacy
Categories
Funding
- Academy of Finland
- EU Framework program 7 [603019]
Ask authors/readers for more resources
Introduction: Infections with oncogenic human papillomaviruses (HPV) globally cause about 9% of cancers in females and 1% of cancers in males. HPV disease burden can be effectively controlled by prophylactic HPV-vaccination provided it has high impact. Areas covered: A unique series of biobank-based and health registry-based studies that exploit randomized intervention cohorts has provided data on population-level safety of HPV vaccination, duration of vaccine-induced protection and impact of gender-neutral HPV vaccination, providing a scientific basis for policies to eradicate oncogenic HPV types and associated diseases worldwide. Expert commentary: The ultimate goal of HPV vaccination is the eradication of high-risk (hr) HPVs. Seventy-five percent coverage gender-neutral vaccination of early adolescents will rapidly eradicate also HPV16 from the general population.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available